Sales & Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Arrow recall benefits Utah Medical: Salt Lake City firm's neonatal sales rise 28% in Q1 as former customers of Arrow International's NeoPICC 1.9 Fr peripheral central catheter, voluntarily recalled in December, purchase Utah Medical's products as replacements, CEO Kevin Cornwell states in April 21 call (1"The Gray Sheet" Jan. 24, 2005, p. 26). In the first quarter, Utah Medical revenue totaled $6.7 mil., up 1% versus the prior-year period. The firm's obstetrics product sales slipped 6%, hampering growth....FDA v. Utah Medical: Exec notes a Department of Justice complaint seeking to halt Utah Medical sales after an FDA inspection cited persistent QSR lapses dating to 2001 is slated for a June 20 pre-trial hearing in Salt Lake City federal court (2"The Gray Sheet" Aug. 23, 2004, In Brief)...
You may also be interested in...
Bausch & Lomb Predicts Strong Sales From PureVision Re-Launch In U.S.
Bausch & Lomb's planned U.S. re-launch of its PureVision silicone hydrogel contact lens in the second quarter could enable a repeat of the firm's 12% constant currency lens sales growth for 2004
Arrow Upgrades Manufacturing/Sales Operations, Reviews LVAD Program
Arrow International expects to spend $40 mil. over the next two years to streamline its global manufacturing operations, the company reported during a Jan. 19 annual shareholders meeting
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.